MedTrace Logo

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

NCT02872259 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-01-14

No results posted yet for this study

Summary

The purpose of the study is to assess the safety and efficacy of BGB324 given together with standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard treatment alone,

Conditions

Interventions

DRUG

BGB324+pembrolizumab

Combination

DRUG

BGB324+dabrafenib and trametinib

Combination

DRUG

pembrolizumab

Monotherapy

DRUG

dabrafenib and trametinib

Combination

Sponsors & Collaborators

  • BerGenBio ASA

    collaborator INDUSTRY

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Oddbjørn Straume, MD PhD · Haukeland University Hospital, 5021 Bergen, Norway

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-13
Primary Completion
2024-05-23
Completion
2024-05-23

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02872259 on ClinicalTrials.gov